JohnAnderson80

5 months ago

$GSK US FDA Adcom Votes (3 Yes; 5 No) overall benefit-risk of belantamab mafodotin in combination with bortezomib and dexamethasone Is Not favorable at the proposed dosage in the proposed patient population - ODAC Meeting (GlaxoSmithKline plc)
(More at https://tradethenews.com/?...